367 related articles for article (PubMed ID: 18981288)
1. N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease.
Mori H; Tonai-Kachi H; Ochi Y; Taniguchi Y; Ohshiro H; Takahashi N; Aihara T; Hirao A; Kato T; Sakakibara M; Kurebayashi Y
J Pharmacol Exp Ther; 2009 Feb; 328(2):671-9. PubMed ID: 18981288
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526).
Ito K; Kinoshita K; Tomizawa A; Inaba F; Morikawa-Inomata Y; Makino M; Tabata K; Shibakawa N
J Pharmacol Exp Ther; 2007 Oct; 323(1):308-17. PubMed ID: 17630360
[TBL] [Abstract][Full Text] [Related]
3. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals.
Hori Y; Matsukawa J; Takeuchi T; Nishida H; Kajino M; Inatomi N
J Pharmacol Exp Ther; 2011 Jun; 337(3):797-804. PubMed ID: 21411494
[TBL] [Abstract][Full Text] [Related]
4. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.
Kwon D; Chae JB; Park CW; Kim YS; Lee SM; Kim EJ; Huh IH; Kim DY; Cho KD
Arzneimittelforschung; 2001; 51(3):204-13. PubMed ID: 11304936
[TBL] [Abstract][Full Text] [Related]
5. Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats.
Satoh H; Inatomi N; Nagaya H; Inada I; Nohara A; Nakamura N; Maki Y
J Pharmacol Exp Ther; 1989 Feb; 248(2):806-15. PubMed ID: 2537418
[TBL] [Abstract][Full Text] [Related]
6. Reversible inhibition of rat gastric H+/K+-ATPase by T-330, 2-[2-dimethylaminobenzyl)sulfinyl]-1-(3-methylpyridine-2-yl)imidazole.
Kinoshita M; Saito N; Noto T; Tamaki H
J Pharmacol Exp Ther; 1996 Apr; 277(1):28-33. PubMed ID: 8613931
[TBL] [Abstract][Full Text] [Related]
7. AHR-9294: a novel inhibitor of H,K-ATPase antagonizes gastric HCl secretion in vivo.
Reenstra WW; Pinkus LM; Bailey J; Smith WL; Droppleman D; Sancilio LF; Forte JG
J Pharmacol Exp Ther; 1992 May; 261(2):737-45. PubMed ID: 1315865
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+,K+-ATPase.
Gedda K; Briving C; Svensson K; Maxvall I; Andersson K
Biochem Pharmacol; 2007 Jan; 73(2):198-205. PubMed ID: 17081503
[TBL] [Abstract][Full Text] [Related]
9. E3710, a new proton pump inhibitor, with a long-lasting inhibitory effect on gastric acid secretion.
Kodama K; Fujisaki H; Kubota A; Kato H; Hirota K; Kuramochi H; Murota M; Tabata Y; Ueda M; Harada H; Kawahara T; Shinoda M; Watanabe N; Iida D; Terauchi H; Yasui S; Miyazawa S; Nagakawa J
J Pharmacol Exp Ther; 2010 Aug; 334(2):395-401. PubMed ID: 20484556
[TBL] [Abstract][Full Text] [Related]
10. H+/K+ ATPase inhibitors in the treatment of acid-related disorders.
Bamford M
Prog Med Chem; 2009; 47():75-162. PubMed ID: 19328290
[No Abstract] [Full Text] [Related]
11. Pharmacological targets in gastro-oesophageal reflux disease.
Piche T; Galmiche JP
Basic Clin Pharmacol Toxicol; 2005 Dec; 97(6):333-41. PubMed ID: 16364047
[TBL] [Abstract][Full Text] [Related]
12. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
Uchiyama K; Wakatsuki D; Kakinoki B; Takeuchi Y; Araki T; Morinaka Y
J Pharm Pharmacol; 1999 Apr; 51(4):457-64. PubMed ID: 10385219
[TBL] [Abstract][Full Text] [Related]
13. New pharmacologic approaches in gastroesophageal reflux disease.
Armstrong D; Sifrim D
Gastroenterol Clin North Am; 2010 Sep; 39(3):393-418. PubMed ID: 20951909
[TBL] [Abstract][Full Text] [Related]
14. Discovery, synthesis, and biological evaluation of novel pyrrole derivatives as highly selective potassium-competitive acid blockers.
Nishida H; Hasuoka A; Arikawa Y; Kurasawa O; Hirase K; Inatomi N; Hori Y; Sato F; Tarui N; Imanishi A; Kondo M; Takagi T; Kajino M
Bioorg Med Chem; 2012 Jun; 20(12):3925-38. PubMed ID: 22579619
[TBL] [Abstract][Full Text] [Related]
15. Control of gastric acid secretion in health and disease.
Schubert ML; Peura DA
Gastroenterology; 2008 Jun; 134(7):1842-60. PubMed ID: 18474247
[TBL] [Abstract][Full Text] [Related]
16. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors.
Shin JM; Cho YM; Sachs G
J Am Chem Soc; 2004 Jun; 126(25):7800-11. PubMed ID: 15212527
[TBL] [Abstract][Full Text] [Related]
17. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases.
Andersson K; Carlsson E
Pharmacol Ther; 2005 Dec; 108(3):294-307. PubMed ID: 16000224
[TBL] [Abstract][Full Text] [Related]
18. Soraprazan: setting new standards in inhibition of gastric acid secretion.
Simon WA; Herrmann M; Klein T; Shin JM; Huber R; Senn-Bilfinger J; Postius S
J Pharmacol Exp Ther; 2007 Jun; 321(3):866-74. PubMed ID: 17369284
[TBL] [Abstract][Full Text] [Related]
19. Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).
Bailey N; Bamford MJ; Brissy D; Brookfield J; Demont E; Elliott R; Garton N; Farre-Gutierrez I; Hayhow T; Hutley G; Naylor A; Panchal TA; Seow HX; Spalding D; Takle AK
Bioorg Med Chem Lett; 2009 Jul; 19(13):3602-6. PubMed ID: 19467868
[TBL] [Abstract][Full Text] [Related]
20. High-throughput screening of potassium-competitive acid blockers.
Kondo M; Kawamoto M; Hasuoka A; Kajino M; Inatomi N; Tarui N
J Biomol Screen; 2012 Feb; 17(2):177-82. PubMed ID: 21940711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
